Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 16;15:17588359221148540. doi: 10.1177/17588359221148540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Selected summary of actionable targets and their targeted therapies with demonstrable clinical efficacy in mCRC.

Source: Adapted from ‘HER2 Signalling Pathway’, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates.

ALK, anaplastic lymphoma kinase; BRAF, serine/threonine-protein kinase B-Raf; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma virus; mAbs, monoclonal antibodies; mCRC, metastatic colorectal cancer; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; NTRK, neurotrophic tyrosine receptor kinase; PI3K, phosphoinositide 3-kinase; ROS1, c-ros oncogene 1; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan or DS-8201; TKIs, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor.